440 related articles for article (PubMed ID: 11368289)
1. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Dunn CJ; Goa KL
Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
[TBL] [Abstract][Full Text] [Related]
2. Risedronate: clinical usage.
Chapurlat RD; Delmas PD
Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
[TBL] [Abstract][Full Text] [Related]
3. Risedronate: a clinical review.
Crandall C
Arch Intern Med; 2001 Feb; 161(3):353-60. PubMed ID: 11176760
[TBL] [Abstract][Full Text] [Related]
4. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
5. Risedronate once a week.
White NJ; Perry CM
Treat Endocrinol; 2003; 2(6):415-20; discussion 421. PubMed ID: 15981945
[TBL] [Abstract][Full Text] [Related]
6. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
[TBL] [Abstract][Full Text] [Related]
7. Review of risedronate in the treatment of osteoporosis.
Geusens P; McClung M
Expert Opin Pharmacother; 2001 Dec; 2(12):2011-25. PubMed ID: 11825332
[TBL] [Abstract][Full Text] [Related]
8. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
[TBL] [Abstract][Full Text] [Related]
9. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Reid DM; Adami S; Devogelaer JP; Chines AA
Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
[TBL] [Abstract][Full Text] [Related]
11. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
12. Risedronate.
Goa KL; Balfour JA
Drugs Aging; 1998 Jul; 13(1):83-91; discussion 92. PubMed ID: 9679211
[TBL] [Abstract][Full Text] [Related]
13. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
[TBL] [Abstract][Full Text] [Related]
14. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
15. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
16. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Dunn CJ; Fitton A; Sorkin EM
Drugs Aging; 1994 Dec; 5(6):446-74. PubMed ID: 7858370
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
Miller PD; Brown JP; Siris ES; Hoseyni MS; Axelrod DW; Bekker PJ
Am J Med; 1999 May; 106(5):513-20. PubMed ID: 10335722
[TBL] [Abstract][Full Text] [Related]
18. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Fogelman I; Ribot C; Smith R; Ethgen D; Sod E; Reginster JY
J Clin Endocrinol Metab; 2000 May; 85(5):1895-900. PubMed ID: 10843171
[TBL] [Abstract][Full Text] [Related]
19. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Giljević Z; Vlak T
Reumatizam; 2006; 53(2):66-71. PubMed ID: 17580558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
